Industry Insights: The World Biosimilar Congress 2015

Who is really impacted by healthcare spend? Is it the pharma companies investing millions in bringing drugs to market? The academics reliant on grants to provide research into new formulas and compounds? The service providers who rely on continued drug development and manufacturing to operate? Not exactly. At the end of the day, it’s the patients and their loved ones …

Total Biopharma interviews Richard Marlus, Amgen's Executive Medical Director

Amgen’s Executive Medical Director, Richard Markus, talks Biosimilars

In the world of biosimilars, there is quite some activity occurring, from a significant number of products under development to regulatory approvals to watch out for. With this in mind, and in preparation for the World Biosimilar Congress 2014, we’ve taken some time to conduct interviews with key members of the speaker faculty who are influential professionals of the biosimilar …